| ¿µ¹® | antibiotics | ÇÑ±Û | Ç×»ýÁ¦ |
|---|---|---|---|
| ¼³¸í | ¹Ì»ý¹°ÀÌ ¸¸µé¾î³»´Â Ç×»ý ¹°Áú·Î µÈ ¾àÁ¦. ´Ù¸¥ ¹Ì»ý¹°À̳ª »ý¹° ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϰųª Á×ÀδÙ. ¹Ì»ý¹°¿¡ ÀÇÇØ »ý»êµÇ¸ç ¹Ì»ý¹°ÀÇ ¹ßÀ° ¶Ç´Â ¾Ç¼ºÁ¾¾çÀÇ Áõ½ÄÀ» ÀúÁöÇÏ´Â ¹°ÁúÀÌ´Ù. ¼÷ÁÖ¿¡ ¹«ÇØÇÑ Ç×»ý¹°ÁúÀº »ç¶÷-µ¿¹°-½Ä¹°ÀÇ ¼¼±Õ°¨¿°ÁõÀÇ Ä¡·á¿¡ ÈÇпä¹ýÁ¦·Î »ç¿ëÇÑ´Ù. ±× ÀÛ¿ë¸ÞÄ¿´ÏÁòÀº ¹Ì»ý¹°ÀÇ ¼¼Æ÷º®À» ÇÕ¼ºÇÏ´Â °ÍÀ» ÀúÇØÇÏ´Â °Í, ÇÙ»ê(DNA, RNA) ÇÕ¼ºÀúÇØ, ´Ü¹éÁú ÇÕ¼ºÀúÇØ, º¸È¿¼ÒÇÕ¼ºÀúÇØ µîÀÌ ÀÖ´Ù. ÀÛ¿ë¸ÞÄ¿´ÏÁò°ú ÈÇб¸Á¶¿¡ µû¶ó ¥â-¶ôްè(Æä´Ï½Ç¸°·ù), ¾Æ¹Ì³ë´ç·ù°è, Åׯ®¶ó»çÀÌŬ¸°°è, Ŭ·Î¶÷Æä´ÏÄݰè, Æú¸®ÆéƼµå°è, ±âŸ(¸°ÄÚ¸¶À̽Å, ¹ÝÄÚ¸¶À̽еî)·Î ºÐ·ùµÈ´Ù. Ç×Á¾¾çÇ×»ý¹°Áú¿¡´Â ¾Æµå¸®¾Æ¸¶À̽Å, ¾ÇƼ³ë¸¶À̽ÅD, ¸¶ÀÌÅ丶À̽ÅC, ºí·¹¿À¸¶À̽еîÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | resistance | ÇÑ±Û | ³»¼º, ÀúÇ×¼º |
|---|---|---|---|
| ¼³¸í | ¨ç ¾à¹°ÀÇ ¹Ýº¹ º¹¿ë¿¡ ÀÇÇØ ¾àÈ¿°¡ ÀúÇÏÇÏ´Â Çö»ó. ¨è ¼¼±Õ µûÀ§ÀÇ º´¿øÃ¼°¡ ÈÇÐ ¿ä¹ýÁ¦³ª Ç×»ý ¹°ÁúÀÇ °è¼Ó »ç¿ë¿¡ ´ëÇÏ¿© ³ªÅ¸³»´Â ÀúÇ×¼º. ¼¼±ÕÀÇ ³»¼ºÈ¹µæÀÇ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇØ¼´Â ¼¼Æ÷ÀÇ ±¸Á¶(¸®Æ÷Á», ¼¼Æ÷¸·) º¯È, ´ë»ç°èÀÇ º¯È, µ¹¿¬º¯ÀÌ µî¿¡ ÀÇÇÑ ¾à¹°°¨¼ö¼º ÀúÇÏ µîÀÌ ÃßÃøµÇ°í ÀÖ´Ù. ÇÑÆí ´Ù¸¥ ¾à¹°¿¡µµ ³»¼ºÀ» ³ªÅ¸³»´Â ±³Â÷³»¼º°ú, ¿©·¯ Á¾·ùÀÇ ¾à¹°¿¡ µ¿½Ã¿¡ ³»¼ºÀ» ȹµæÇÑ »óŸ¦ ´ÙÁ¦ ³»¼ºÀ̶ó°í ÇÑ´Ù. 3. ȯ°æ Á¶°ÇÀÇ º¯È¿¡ °ßµô ¼ö ÀÖ´Â »ý¹°ÀÇ ¼ºÁú. ³»¿¼º, ³»ÇѼº µûÀ§°¡ ÀÖ´Ù. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| ¿µ¹® | resistance | ÇÑ±Û | ÀúÇ× |
|---|---|---|---|
| ¼³¸í | ¨ç¾à¹°ÀÇ ¹Ýº¹ º¹¿ë¿¡ ÀÇÇØ ¾àÈ¿°¡ ÀúÇÏÇÏ´Â Çö»ó. ¨è ¼¼±Õ µûÀ§ÀÇ º´¿øÃ¼°¡ ÈÇÐ ¿ä¹ýÁ¦³ª Ç×»ý ¹°ÁúÀÇ °è¼Ó »ç¿ë¿¡ ´ëÇÏ¿© ³ªÅ¸³»´Â ÀúÇ×¼º. ¼¼±ÕÀÇ ³»¼ºÈ¹µæÀÇ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇØ¼´Â ¼¼Æ÷ÀÇ ±¸Á¶(¸®Æ÷Á», ¼¼Æ÷¸·) º¯È, ´ë»ç°èÀÇ º¯È, µ¹¿¬º¯ÀÌ µî¿¡ ÀÇÇÑ ¾à¹°°¨¼ö¼º ÀúÇÏ µîÀÌ ÃßÃøµÇ°í ÀÖ´Ù. ÇÑÆí ´Ù¸¥ ¾à¹°¿¡µµ ³»¼ºÀ» ³ªÅ¸³»´Â ±³Â÷³»¼º°ú, ¿©·¯ Á¾·ùÀÇ ¾à¹°¿¡ µ¿½Ã¿¡ ³»¼ºÀ» ȹµæÇÑ »óŸ¦ ´ÙÁ¦ ³»¼ºÀ̶ó°í ÇÑ´Ù. ¨é ȯ°æ Á¶°ÇÀÇ º¯È¿¡ °ßµô ¼ö ÀÖ´Â »ý¹°ÀÇ ¼ºÁú. ³»¿¼º, ³»ÇѼº µûÀ§°¡ ÀÖ´Ù. |
||
| IR | drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat... |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| SR | sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat... |
| TEF | Tracheo-Esophageal Fistula ? Tx 1. Infant Warmer  ... |
| NOABX | no antibiotics |
| AGs | Aminoglycoside antibiotics |
|---|---|
| AB | Antibiotics |
| APC resistance | Resistance to activated protein C |
| TGR | 6-thioguanine resistance |
| APCR | Activated Protein C Resistance |
PDGF (Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
| antibiotics | Drugs that fight infections. (12 Dec 1998) |
|---|---|
| antibiotics, aminoglycoside | Antibiotics whose structure contains amino sugars attached to an aminocyclitol ring (hexose nucleus) by glycosidic bonds. Aminoglycoside antibiotics are derived from various species of streptomyces and micromonospora or are produced synthetically. They act by inhibiting protein synthesis. (12 Dec 1998) |
| antibiotics, anthracycline | Antibiotics which have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to a sugar molecule. These antibiotics have potent antineoplastic activity. The two best known members of this group are daunorubicin and doxorubicin. Since these agents intercalate with DNA, many DNA functions are adversely affected. Futhermore they interact with cell membranes thereby altering their functions and also generate hydrogen peroxide and hydroxy radicals which are highly destructive to cells. (12 Dec 1998) |
| antibiotics, antifungal | Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases. (12 Dec 1998) |
| antibiotics, antineoplastic | Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms. (12 Dec 1998) |
| antibiotics, antitubercular | Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. (12 Dec 1998) |
| antibiotics, combined | Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antibiotics, glycopeptide | Antibiotics whose structure contains one or more cyclic peptides to which are attached one or more deoxy sugars in glycosidic linkage. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| antibiotics, lactam | Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins; their analogs and derivatives, such as the penem (or penam) compounds; clavulanic acids; and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases. (12 Dec 1998) |
| antibiotics, macrolide | A group of antibiotics containing a macrocyclic lactone ring linked glycosidically to one or more sugar moieties. These antibiotics are produced by certain species of streptomyces. They often inhibit protein synthesis by binding to the 50s subunits of 70s ribosomes. (12 Dec 1998) |
| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| antibiotics, tetracycline | <chemical> Broad-spectrum natural and semisynthetic antibiotics with a naphthacene structure obtained from various streptomyces species. Pharmacological action: protein synthesis inhibitor. (12 Dec 1998) |
| intravenous antibiotics | The administration of an antibiotic solution into the venous circulation. (27 Sep 1997) |
| topical antibiotics | A ointment (or cream) based medication that kills bacteria. Examples include Neosporin, Bactroban, Garamycin, bacitracin, gentamicin, mupirocin, neomycin, silver sulphasalazine, chloramphenicol and clindamycin. (27 Sep 1997) |
| airway resistance | The opposition of the tracheobronchial tree to air flow: the mouth-to-alveoli pressure difference divided by the air flow. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|